Data compiled by Redley Lamar · ChainSifter Intelligence
5Suppliers
2Customers
2Debt Items
5Related Chains
Source-Backed Evidence Depth
Indaptus Therapeutics, Inc. (INDP) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
10Total relationships
2Distinct source URLs
8High confidence
0.853Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Indaptus Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
WAINWRIGHT
WAINWRIGHT
92%
In June 2022, we entered into the ATM Agreement with Wainwright, which was amended on September 1, 2022, pursuant to which we may offer and sell, from time to time through Wainwright, shares of our c…
CONTRACT-MANUFACTURING-ORGANIZATIONS
CONTRACT-MANUFACTURING-ORGANIZATIONS
90%
Research and development expenses consist primarily of fees paid to contract research organizations, or CROs, and contract manufacturing organizations, or CMOs, as well as compensation expenses for c…
CONTRACT-RESEARCH-ORGANIZATIONS
CONTRACT-RESEARCH-ORGANIZATIONS
90%
Research and development expenses consist primarily of fees paid to contract research organizations, or CROs, and contract manufacturing organizations, or CMOs, as well as compensation expenses for c…
DAVID-E-LAZAR
DAVID-E-LAZAR
85%
On December 22, 2025, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with David E. Lazar, pursuant to which he agreed to purchase from the Company 300,000 shares …
Reciprocal relationship from ENLV graph: Reciprocal relationship from INDP graph: Reciprocal relationship from ENLV graph: fair value of share-based payment awards represent management’s best estimat…
Indaptus Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
DAVID-E-LAZAR
DAVID-E-LAZAR
92%
he agreed to purchase from the Company 300,000 shares of Series AA Convertible Preferred Stock and 700,000 shares of Series AAA Convertible Preferred Stock
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
as well as a decrease in payroll and related expenses of approximately $0.4 million due to reductions to headcount and base salaries. General and Administrative Expenses Our general and administrativ…
Indaptus Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
INDP-DEBT-10278
Warrants outstanding: 1788729
90%
xbrl warrant detail from xbrl 2026-03-31.
INDP-DEBT-10279
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
Indaptus Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Indaptus Therapeutics, Inc..
Indaptus Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
INDP-OWNER-DANSKE-BANK-A-S
DANSKE BANK A/S
90%
13F overlay lists DANSKE BANK A/S as top holder; 1 tracked holders.
Indaptus Therapeutics, Inc. Extended Supply Chain Network
